Medivation (MDVN) Q2 2012 Earnings Call August 09, 2012 4:30 pm ET Executives Anne Bowdidge David T. Hung - Chief Executive Officer, President and Executive Director C. Patrick Machado - Chief Financial Officer, Principal Accounting Officer, Chief Business Officer and Secretary Lynn Seely - Chief Medical Officer and Senior Vice President Cheryl Cohen - Chief Commercial Officer Analysts John Beshai Kimberly Lee - ThinkEquity LLC, Research Division Yaron Werber - Citigroup Inc, Research Division Y. Katherine Xu - William Blair & Company L.L.C., Research Division Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division Lee Kalowski - Crédit Suisse AG, Research Division Biren Amin - Jefferies & Company, Inc., Research Division Raghuram Selvaraju - Aegis Capital Corporation, Research Division Ling Wang - Summer Street Research Partners Eric Schmidt - Cowen and Company, LLC, Research Division Howard Liang - Leerink Swann LLC, Research Division PresentationOperator
Good day, everyone, and welcome to Medivation's scheduled conference call. This call is being recorded. [Operator Instructions] I would now like to turn the call over to Anne Bowdidge, Senior Director of Investor Relations. Please go ahead. Anne Bowdidge Thank you for joining us. On the call today from Medivation are Dr. David Hung, President and CEO; Patrick Machado, Chief Business and Financial Officer; Dr. Lynn Seely, Chief Medical Officer; and Cheryl Cohen, Chief Commercial Officer. We issued a press release earlier today that you can find on our website at www.medivation.com. Before we begin, I'd like to remind you that various remarks we make on this call contain forward-looking statements that are made under the Safe Harbor provisions of the securities laws, including statements regarding the potential future regulatory approval and commercialization of enzalutamide and the timing thereof; continued clinical development of enzalutamide; potential future clinical trial events or results; the therapeutic potential and safety profiles of our product candidates; our future opportunities and milestones; and financial guidance for the remainder of 2012, including projected revenue recognition, operating expenses, capital expenditures and receipt of development milestone payments.